Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

5-fluorouracil (5-Fu) in the treatment of prostatic hyperplasia

  • 15 Accesses

  • 3 Citations


A prospective study of 5-Fu in the treatment of prostatic hyperplasia was commenced in 1981. The short term results were fair in 70% of 43 patients. Atrophy of the glandular tissue could be observed on histopathologic examinaion. The study showed that the larger the glandular component the better was the therapeutic effect. If abundant fibromuscular tissue was present in the gland the treatment was unsatisfactory. Abnormal anatomy of the bladder neck, represented a contraindication to medical treatment.

This is a preview of subscription content, log in to check access.


  1. 1.

    Altwein JE (1974) A relationship of benign prostatic hypertrophy with hormon. Urologe 13:41

  2. 2.

    Basinger GT et al (1974) Antiandrogenic effect of spironolactone in rats. J Urol 111:77

  3. 3.

    Chen L et al (1976) Mechanism of action of the sex steroid hormons. New Engl J Med 294:1322

  4. 4.

    Dorfman RI (1963) The antiandrogenic activity of 5-Fluorouracil. Steroids 2:555

  5. 5.

    Horton R, et al (1975) Altered blood androgens in elderly men with prostatic hyperplasia. J Clin Endocrinol Metab 41:793

  6. 6.

    Smith RB et al (1973) Cyproterone acetate in the treatment of advanced carcinoma of prostate. J Urol 110:106

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wei, X.Y., Zhou, X.M. 5-fluorouracil (5-Fu) in the treatment of prostatic hyperplasia. Urol. Res. 15, 35–37 (1987). https://doi.org/10.1007/BF00256333

Download citation

Key words

  • Prostatic hyperplasia
  • 5-Fu
  • Medical treatment